Clinical Trial Update: Angiomax in Patients With HIT/HITTS Type II Undergoing CPB [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Angiomax (bivalirudin) in patients with heparin-induced thrombocytopenia undergoing cardiopulmonary bypass has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Heparin-induced Thrombocytopenia

Drugs mentioned

• Angiomax (bivalirudin)

Snippet

Sponsor: The Medicines Company | Conditions: Cardiovascular Disease, Coronary Artery Bypass Surgery | Phase 3 | Status: COMPLETED